Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    Amylopectin

    go.drugbank.com/drugs/DB14927
    Experimental

    Amylopectin is under investigation in clinical trial NCT01708694 (Role of Slowly Digesible Starch on Diabetes Risk Factors).

  2. Drug

    Pexmetinib

    go.drugbank.com/drugs/DB16294
    Investigational

    Pexmetinib is under investigation in clinical trial NCT04074967 (Study of ARRY-614 Plus Either Nivolumab or Ipilimumab).

  3. Drug

    Cafedrine

    go.drugbank.com/drugs/DB12926
    Investigational

    Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

  4. Drug

    Theodrenaline

    go.drugbank.com/drugs/DB12927
    Investigational

    Theodrenaline is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

  5. Drug

    Equus caballus dander

    go.drugbank.com/drugs/DB11021
    Approved

    Equus caballus dander is the dander of Equus caballus. Equus caballus dander is used in allergenic testing.

  6. Drug

    Neuropeptide Y

    go.drugbank.com/drugs/DB11788
    ApprovedInvestigationalWithdrawn

    Neuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.

  7. Drug

    N-acetylsulfanilyl chloride

    go.drugbank.com/drugs/DB12337
    Investigational

    ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.

  8. Drug

    Carlumab

    go.drugbank.com/drugs/DB12718
    ApprovedWithdrawn

    Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.

  9. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  10. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.